| 000 | 01893 a2200565 4500 | ||
|---|---|---|---|
| 005 | 20250516072531.0 | ||
| 264 | 0 | _c20120525 | |
| 008 | 201205s 0 0 eng d | ||
| 022 | _a1528-0020 | ||
| 024 | 7 |
_a10.1182/blood-2011-09-382846 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aPowell, Jerry S | |
| 245 | 0 | 0 |
_aSafety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients. _h[electronic resource] |
| 260 |
_bBlood _cMar 2012 |
||
| 300 |
_a3031-7 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 |
_aFactor VIII _xadministration & dosage |
| 650 | 0 | 4 | _aHalf-Life |
| 650 | 0 | 4 |
_aHemophilia A _xblood |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImmunoglobulin Fc Fragments _xadministration & dosage |
| 650 | 0 | 4 | _aInfusion Pumps |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMetabolic Clearance Rate |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aReceptors, Fc _xadministration & dosage |
| 650 | 0 | 4 |
_aRecombinant Fusion Proteins _xadministration & dosage |
| 650 | 0 | 4 | _aTime Factors |
| 650 | 0 | 4 | _aYoung Adult |
| 650 | 0 | 4 |
_avon Willebrand Factor _xanalysis |
| 700 | 1 | _aJosephson, Neil C | |
| 700 | 1 | _aQuon, Doris | |
| 700 | 1 | _aRagni, Margaret V | |
| 700 | 1 | _aCheng, Gregory | |
| 700 | 1 | _aLi, Ella | |
| 700 | 1 | _aJiang, Haiyan | |
| 700 | 1 | _aLi, Lian | |
| 700 | 1 | _aDumont, Jennifer A | |
| 700 | 1 | _aGoyal, Jaya | |
| 700 | 1 | _aZhang, Xin | |
| 700 | 1 | _aSommer, Jurg | |
| 700 | 1 | _aMcCue, Justin | |
| 700 | 1 | _aBarbetti, Margaret | |
| 700 | 1 | _aLuk, Alvin | |
| 700 | 1 | _aPierce, Glenn F | |
| 773 | 0 |
_tBlood _gvol. 119 _gno. 13 _gp. 3031-7 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1182/blood-2011-09-382846 _zAvailable from publisher's website |
| 999 |
_c21441453 _d21441453 |
||